Pro-fibrotic immune cell detected in lungs of long COVID-19 patients

IPF treatment ISM001-055 safe, improves lung function, data show

Insilico Medicine’s ISM001-055 was generally safe and improved lung function in people with idiopathic pulmonary fibrosis (IPF), according to top-line data from a Phase 2a trial. The trial (NCT05938920) enrolled 71 patients with IPF across 21 sites in China who were randomly assigned to receive one of…

The big shift: My decision to stop working

I was recently asked when I stopped working and how I knew it was time. First, let me tell you: It wasn’t an easy decision. My idiopathic pulmonary fibrosis (IPF) diagnosis came on Jan. 31, 2017. At the time I was the senior vice president for a U.S.

Nerandomilast Phase 3 clinical trial meets its primary goal in IPF

A Phase 3 clinical trial testing Boehringer Ingelheim’s oral investigational treatment nerandomilast in people with idiopathic pulmonary fibrosis (IPF) has met its primary goal of demonstrating the therapy outperformed a placebo at improving lung function or preventing its decline after a year, recently announced top-line data shows.

The need for pulmonary fibrosis awareness never ends

When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, the disease was a mystery to me. I’ve shared before that when my wife, Susan, and I left the clinic following my diagnosis, we began to search for information from the parking garage. That thirst for…

$15K award goes to researcher for work into IPF disease risk factors

A University of Colorado professor has won the 2024 Alton Ochsner Award Relating Smoking and Disease for his work into how genetic and environmental factors, including smoking, contribute to a person’s risk of idiopathic pulmonary fibrosis (IPF) — when the disease is due to unknown causes. The $15,000 prize…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums